After $105M funding round, ALX Oncology nabs FDA fast-track tag for cancer hopeful

After $105M funding round, ALX Oncology nabs FDA fast-track tag for cancer hopeful

Source: 
Fierce Biotech
snippet: 

It’s been a good month for ALX Oncology: After getting off a meaty $105 million series C last week, it’s started this week with two fast-track labels for its experimental drug.